Head to Head Comparison: Crescent Biopharma (NASDAQ:CBIO) versus INmune Bio (NASDAQ:INMB)

INmune Bio (NASDAQ:INMB) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Profitability

This table compares INmune Bio and Crescent Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Crescent Biopharma	N/A	-101.50%	-86.86%

Analyst Recommendations

This is a summary of recent recommendations for INmune Bio and Crescent Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1	0	0	1	2.50
Crescent Biopharma	1	1	2	2	2.83

Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 44.67%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than INmune Bio.

Institutional and Insider Ownership

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

INmune Bio has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Valuation and Earnings

This table compares INmune Bio and Crescent Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50,000.00	1,393.05	-$45.93 million	($0.67)	-3.75
Crescent Biopharma	$10.84 million	70.10	-$153.94 million	($6.72)	-3.04

INmune Bio has higher earnings, but lower revenue than Crescent Biopharma. INmune Bio is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Crescent Biopharma beats INmune Bio on 9 of the 14 factors compared between the two stocks.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.